PD-1 / PD-L1 Landscape
The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased and scientifically curated analysis of the PD-1 / PD-L1 landscape and agents in development, in clinical trials, and approved by the FDA, EMA, NMPA, and PDMA. Data is based on information collected from numerous trusted and publicly available sources. We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication.
Our Latest PD-1 / PD-L1 Landscape Update
The clinical development of PD-1/PD-L1 agents is at the epicenter of immuno-oncology drug development. We created an interactive dashboard of active interventional trials with approved and other PD-1/PD-L1 agents as well as targets used in combination therapy trials.
Anti-PD-1/PD-L1 Monoclonal Antibody Clinical Trial Landscape.
PD-1/PD-L1 Approval Timelines
The growth of PD-1/PD-L1 is reflected globally. We created timelines of government approvals to demonstrate the growth in this area. Find out more below:
Regulatory Approval Timeline of Active Immunotherapies
PD-1/PD-L1 Landscape Analysis Publications
PD-1/PD-L1 landscape publications include:
- “Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape” in Nature Reviews Drug Discovery (February 2022)
- “Combinations take centre stage in PD1/PDL1 inhibitor clinical trials” in Nature Reviews Drug Discovery (November 2020)
- “Trends in clinical development of PD-1/PD-L1 inhibitors” in Nature Reviews Drug Discovery (November 2019)
- “The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors” in Nature Reviews Drug Discovery (November 2018)
READ MORE IO LANDSCAPE PUBLICATIONS
Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets.
DOWNLOAD A PDF OF THE LATEST CRI LANDSCAPE FIGURES
Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.
Subscribe to our email newsletter to receive the latest updates on our landscape analyses.
Do you want more information on the Clinical Accelerator? Contact us.
IO Landscapes
Stay up to date
Join our email list for updates on cancer immunotherapy research, events, and opportunities to get involved with the Cancer Research Institute. Sign up below and be a force for change in the fight against cancer.